DHR Danaher Corporation
Health Care · Life Sciences Tools & Services · close $229.04 (2026-10-16) · latest quarter in EDGAR: 2026-06-26
Danaher Corporation (DHR) has a ThetaGrade House Rating of 48/100 (grade D), ranking #53 of 150 in Health Care. Its strongest pillars are analyst sentiment (83) and cash flow (65); its weakest is valuation (34). TTM revenue growth is 4.6% and operating margin 20.4%.
Data as of .
Analyst sentiment
weight 7.5% · 83| Consensus score (1–5) (3.8%) | derived | 97 |
| 90-day net rating shift (3.8%) | derived | 49 |
Growth
weight 30.83% · 45| Revenue growth YoY (TTM) (12.3%) | 4.6% | 22 |
| EPS growth YoY (TTM) (12.3%) | 19.7% | 57 |
| Revenue acceleration (6.2%) | 1.9% | 68 |
Profitability
weight 18.5% · 49| Operating margin (9.9%) | 20.4% | 70 |
| 4Q gross-margin change (8.6%) | -1.1% | 24 |
Balance sheet
weight 18.5% · 36| Net debt / EBITDA (9.9%) | 3.44× | 20 |
| Current ratio (4.9%) | 1.65 | 32 |
| Interest coverage (3.7%) | 19.35× | 82 |
Cash flow
weight 12.33% · 65| FCF margin (6.2%) | 21.4% | 77 |
| FCF yield (6.2%) | 3.3% | 53 |
Valuation
weight 12.33% · 34| P/E (inverted) (6.2%) | 40.61× | 29 |
| EV/Sales (inverted) (6.2%) | 7.22× | 39 |
Technicals (EOD)
| RSI(14) | 62.5 |
| EMA 9 / 21 | 224.12 / 220.30 |
| 200-day SMA | 201.32 |
| Volume vs 20d avg | 0.75× |
| 20-day return | 7.8% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like DHR's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is DHR's House Rating?
- DHR scores 48 out of 100 (grade D) as of 2026-10-16, ranking #53 of 150 Health Care stocks we cover.
- What do analysts say about DHR?
- ThetaGrade's analyst-sentiment pillar for DHR scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does DHR report earnings next?
- We do not have a reliable estimate for DHR's next earnings date (irregular SEC filing history); a rough window is 2026-07-29 to 2027-01-11. Check the company's investor-relations page.
- Is DHR a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology